Key facts
- This page summarizes James Christopher Barry's Form 4 filing for NUVASIVE INC.
- 6 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 05 Sep 2023, 16:30.
James Christopher Barry - 01 Sep 2023 Form 4 Insider Report for NUVASIVE INC
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- N/A
- Reported as of
- 01 Sep 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Sep 2023, 16:30:36 UTC
- Prior SEC filing
- 03 Mar 2023
- Next SEC filing
- 13 Oct 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Nathaniel B. Sisitsky, Attorney-in-Fact for James Christopher Barry
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
James Christopher Barry filed Form 4 for NUVASIVE INC on 05 Sep 2023.
Change
- Previous filing in this sequence was filed on 03 Mar 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NUVA
transaction
Common Stock, par value $0.001 per share
Disposed to Issuer
- Transaction value
- Shares
- -72,997
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 01 Sep 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NUVA
transaction
Derivative
Restricted Stock Unit
Disposed to Issuer
- Transaction value
- $0
- Shares
- -38,199
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Sep 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 38,199
- Exercise price
- Footnotes
- F2, F3
NUVA
transaction
Derivative
Restricted Stock Unit
Disposed to Issuer
- Transaction value
- $0
- Shares
- -45,864
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Sep 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 45,864
- Exercise price
- Footnotes
- F2, F3
NUVA
transaction
Derivative
Restricted Stock Unit
Disposed to Issuer
- Transaction value
- $0
- Shares
- -120,694
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Sep 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 120,694
- Exercise price
- Footnotes
- F2, F3
NUVA
transaction
Derivative
Performance Restricted Stock Unit
Disposed to Issuer
- Transaction value
- $0
- Shares
- -38,199
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Sep 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 38,199
- Exercise price
- Footnotes
- F2, F4
NUVA
transaction
Derivative
Performance Restricted Stock Unit
Disposed to Issuer
- Transaction value
- $0
- Shares
- -45,864
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Sep 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 45,864
- Exercise price
- Footnotes
- F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
James Christopher Barry is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 4 footnotes
Footnote F1
Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares.
Footnote F2
Represented a contingent right to receive one share of the Issuer's common stock upon vesting.
Footnote F3
Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions) as applied to the corresponding Issuer restricted stock unit award as of immediately prior to the Effective Time.
Footnote F4
Pursuant to the Merger Agreement, at the Effective Time, each performance restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio and with applicable performance conditions deemed to be achieved at 100% of the target performance level. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions but excluding performance-based vesting conditions) as applied to the corresponding Issuer performance restricted stock unit award subject to such award as of immediately prior to the Effective Time.